The Design and Synthesis of N-Xanthone Benzenesulfonamides as Novel Phosphoglycerate Mutase 1 (PGAM1) Inhibitors
Open Access
Abstract
Upregulation of phosphoglycerate mutase 1 (PGAM1) has been identified as one common phenomenon in a variety of cancers. Inhibition of PGAM1 provides a new promising therapeutic strategy for cancer treatment. Herein, based on our previous work, a series of new N-xanthone benzenesulfonamides were discovered as novel PGAM1 inhibitors. The representative molecule 15h, with an IC50 of 2.1 μM, showed an enhanced PGAM1 inhibitory activity and higher enzyme inhibitory specificity compared to PGMI-004A, as well as a slightly improved antiproliferative activity.Keywords
Funding Information
- Chinese National Natural Science Foundation (21472026)
- Shanghai Municipal Committee of Science and Technology (14XD1400300)
- the program for Shanghai Rising Star (15QA1400300)
This publication has 29 references indexed in Scilit:
- Novel drugs that target the metabolic reprogramming in renal cell cancerCancer & Metabolism, 2016
- Cancer metabolism: a therapeutic perspectiveNature Reviews Clinical Oncology, 2016
- Targeting glucose metabolism in patients with cancerCancer, 2013
- Metabolic targets for cancer therapyNature Reviews Drug Discovery, 2013
- Cancer Cell Metabolism: One Hallmark, Many FacesCancer Discovery, 2012
- Targeting cancer metabolism: a therapeutic window opensNature Reviews Drug Discovery, 2011
- Otto Warburg's contributions to current concepts of cancer metabolismNature Reviews Cancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Understanding the Warburg Effect: The Metabolic Requirements of Cell ProliferationScience, 2009
- Cancer Cell Metabolism: Warburg and BeyondCell, 2008